58971-11-2

Basic information

• Product Name: 3-BROMOPHENETHYLAMINE
• Synonyms: 3-BROMOPHENETHYLAMINE;2-(3-BROMO-PHENYL)-ETHYLAMINE;RARECHEM AL BW 0207;3-BROMOPHENETHYLAMINE 99%;3-BROMOPHENETHYLAIME;2-(3-BROMOPHENYL)ETHANAMINE;3-Bromobenzeneethylamine;3-Bromophenethylamine,99%
• CAS NO: 58971-11-2
• Molecular Formula: C₈H₁₀BrN
• Molecular Weight: 200.08
• EINECS: 1533716-785-6
• Product Categories: Amines;C8;Nitrogen Compounds;Building Blocks;Chemical Synthesis;Nitrogen Compounds;Organic Building Blocks
• Mol File: 58971-11-2.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 239-240 °C(lit.)
• Flash Point: >230 °F
• Appearance: Clear colorless to light yellow/Liquid
• Density: 1.406 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0103mmHg at 25°C
• Refractive Index: n20/D 1.5740(lit.)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.83±0.10(Predicted)
• CAS DataBase Reference: 3-BROMOPHENETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMOPHENETHYLAMINE(58971-11-2)
• EPA Substance Registry System: 3-BROMOPHENETHYLAMINE(58971-11-2)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-27-36/37/39-45
• RIDADR: UN 2735 8/PG 2
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: Ⅱ
• Hazardous Substances Data: 58971-11-2(Hazardous Substances Data)

Usage

Chemical Properties

clear colorless to light yellow liquid

InChI:InChI=1/C8H10BrN/c9-8-3-1-2-7(6-8)4-5-10/h1-3,6H,4-5,10H2

Upstream product

• 115665-95-7 3-bromo-β-nitro-styrene 
• 31938-07-5 (3-bromophenyl)acetonitrile 
• 3132-99-8 m-bromobenzoic aldehyde 
• 2039-86-3 3-bromostyrene 
• 131567-05-0 (S)-(+)-2-(3-bromophenyl)oxirane 
• 109347-40-2 2-(3-bromophenyl)acetaldehyde 
• 30163-20-3 2-amino-3-(3-bromophenyl)propanoic acid 
• 14473-91-7 3-bromocinnamic acid 

Downstream Products

• 857795-55-2 2-(3,4-dimethoxy-2-nitro-phenyl)-acetic acid-(3-bromo-phenethylamide) 
• 371222-76-3 N-(3-bromophenethyl)isobutyramide 
• 1057338-26-7 N-[2-(3-bromo-phenyl)-ethyl]-2-chloro-benzamide 
• 774214-05-0 2-(3-bromophenyl)-N,N-dimethylethanamine 
• 153732-25-3 [2-(3-bromophenyl)ethyl]carbamic acid tert-butyl ester 
• 947330-91-8 N-[2-(3-bromophenyl)ethyl]benzenesulfonamide 
• 858855-85-3 (3-bromo-phenethyl)-(3,4-dimethoxy-2-nitro-styryliden)-amine 
• 215797-81-2 N-(3-bromophenethyl)-2,2,2-trifluoroacetamide 
• 594861-82-2 (5R)-3-[6-({4-[3-(2-aminoethyl)phenyl]but-3-ynyl}oxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one 
• 259538-59-5 2-(3'-vinyl-phenyl)-ethylamine 
• 785032-26-0 2-(3-bromophenyl)-N-methylethanamine 
• 1180007-75-3 C₉H₉BrF₃NO₂S 
• 1243204-93-4 N-[2-(3-bromophenyl)ethyl]-3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzamide 
• 1046138-08-2 2-(3-Bromophenyl)-N-((7-methoxy-2-(thiophen-3-yl)quinolin-3-yl)methyl)ethanamine 

Relevant articles and documents

Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior

We have shown that CB1 receptor negative allosteric modulators (NAMs) attenuated the reinstatement of cocaine-seeking behaviors in rats. In an effort to further define the structure-activity relationships and assess the druglike properties of the 3-(4-chlorophenyl)-1-(phenethyl)urea-based CB1 NAMs that we recently reported, we introduced substituents of different electronic properties and sizes to the phenethyl group and evaluated their potency in CB1 calcium mobilization, cAMP, and GTPγS assays. We found that 3-position substitutions such as Cl, F, and Me afforded enhanced CB1 potency, whereas 4-position analogues were generally less potent. The 3-chloro analogue (31, RTICBM-189) showed no activity at >50 protein targets and excellent brain permeation but relatively low metabolic stability in rat liver microsomes. Pharmacokinetic studies in rats confirmed the excellent brain exposure of 31 with a brain/plasma ratio Kp of 2.0. Importantly, intraperitoneal administration of 31 significantly and selectively attenuated the reinstatement of the cocaine-seeking behavior in rats without affecting locomotion.

Combined Photoredox/Enzymatic C?H Benzylic Hydroxylations

Chemical transformations that install heteroatoms into C?H bonds are of significant interest because they streamline the construction of value-added small molecules. Direct C?H oxyfunctionalization, or the one step conversion of a C?H bond to a C?O bond, could be a highly enabling transformation due to the prevalence of the resulting enantioenriched alcohols in pharmaceuticals and natural products,. Here we report a single-flask photoredox/enzymatic process for direct C?H hydroxylation that proceeds with broad reactivity, chemoselectivity and enantioselectivity. This unified strategy advances general photoredox and enzymatic catalysis synergy and enables chemoenzymatic processes for powerful and selective oxidative transformations.

GPR40 receptor stimulant, and preparation method, pharmaceutical composition and application thereof

The invention discloses a GPR40 receptor stimulant, and a preparation method, a pharmaceutical composition and application thereof. The invention particularly discloses a GPR40 receptor stimulant shown in general formula (I) and pharmacologically acceptable salt thereof, a preparation process of the compound, a pharmaceutical composition containing the compound of general formula (I), and application of the compound and the pharmaceutical composition in anti-diabetes.